Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs.

The School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin hosted the "1st Workshop on Drug Transporters in the Lungs" in September 2016 to discuss the impact of transporters on pulmonary drug disposition and their roles as drug targets in lung disease. The workshop brought together about 30 scientists from academia and pharmaceutical industry from Europe and Japan and addressed the primary questions: What do we know today, and what do we need to know tomorrow about transporters in the lung? The 3 themes of the workshop were: (1) techniques to study drug transporter expression and actions in the lungs; (2) drug transporter effects on pulmonary pharmacokinetics-case studies; and (3) transporters as drug targets in lung disease. Some of the conclusions of the workshop were: suitable experimental models that allow studies of transporter effects are available; data from these models convincingly show a contribution of both uptake and efflux transporters on pulmonary drug disposition; the effects of transporters on drug lung PK is now better conceptualized; some transporters are associated with lung diseases. However, more work is needed to establish which of the available models best translate to the clinical situation.

[1]  E. Bäckström,et al.  Lung Retention by Lysosomal Trapping of Inhaled Drugs Can Be Predicted In Vitro With Lung Slices. , 2016, Journal of pharmaceutical sciences.

[2]  R. Mehta,et al.  Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study , 2013, International journal of chronic obstructive pulmonary disease.

[3]  Ning Li,et al.  Tissue distribution and chemical induction of multiple drug resistance genes in rats. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[4]  Lee Campbell,et al.  Expression and Transport Functionality of FcRn within Rat Alveolar Epithelium: A Study in Primary Cell Culture and in the Isolated Perfused Lung , 2005, Pharmaceutical Research.

[5]  C. Bosquillon,et al.  Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs? , 2010, Journal of pharmaceutical sciences.

[6]  Per Bäckman,et al.  Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition. , 2017, Journal of aerosol medicine and pulmonary drug delivery.

[7]  Y. Sugiyama,et al.  Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.

[8]  C. Ehrhardt,et al.  Beta-2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1. , 2015, Molecular pharmaceutics.

[9]  V. Schuster,et al.  Identification and characterization of a prostaglandin transporter. , 1995, Science.

[10]  W. Seeger,et al.  Potential of the isolated lung technique for the examination of sildenafil absorption from lung-delivered poly(lactide-co-glycolide) microparticles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Hans Lennernäs,et al.  Drug Absorption from the Isolated Perfused Rat Lung–Correlations with Drug Physicochemical Properties and Epithelial Permeability , 2003, Journal of drug targeting.

[12]  D. Roerig,et al.  KINETIC CHARACTERIZATION OF P-GLYCOPROTEIN-MEDIATED EFFLUX OF RHODAMINE 6G IN THE INTACT RABBIT LUNG , 2004, Drug Metabolism and Disposition.

[13]  H. Koepsell,et al.  Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. , 2005, American journal of respiratory cell and molecular biology.

[14]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  Nicolas Grégoire,et al.  Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 2. Colistin , 2014, Antimicrobial Agents and Chemotherapy.

[16]  M. Sakagami,et al.  Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: effects of temperature and metabolic inhibitors. , 2002, Journal of pharmaceutical sciences.

[17]  Carsten Ehrhardt,et al.  Transport mechanisms at the pulmonary mucosa: implications for drug delivery , 2016, Expert opinion on drug delivery.

[18]  B. Forbes,et al.  Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice. , 2008, The Journal of pharmacy and pharmacology.

[19]  T. Terasaki,et al.  Validation of uPA/SCID Mouse with Humanized Liver as a Human Liver Model: Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases by LC-MS/MS , 2014, Drug Metabolism and Disposition.

[20]  Terry R Stouch,et al.  Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.

[21]  B. Milleron,et al.  MDR1-Pgp 170 expression in human bronchus. , 1997, The European respiratory journal.

[22]  M. Gumbleton,et al.  Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. , 2013, Journal of pharmaceutical sciences.

[23]  Nicolas Grégoire,et al.  Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 3. Tobramycin , 2014, Antimicrobial Agents and Chemotherapy.

[24]  D. Postma,et al.  Multidrug resistance related molecules in human and murine lung. , 2002, Journal of clinical pathology.

[25]  T. Terasaki,et al.  Correlation of Organic Cation/Carnitine Transporter 1 and Multidrug Resistance-Associated Protein 1 Transport Activities With Protein Expression Levels in Primary Cultured Human Tracheal, Bronchial, and Alveolar Epithelial Cells. , 2016, Journal of pharmaceutical sciences.

[26]  Timothy G. Turkington,et al.  Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine , 2010, Proceedings of the National Academy of Sciences.

[27]  M. Gumbleton,et al.  Absorption of ipratropium and l-carnitine into the pulmonary circulation of the ex-vivo rat lung is driven by passive processes rather than active uptake by OCT/OCTN transporters. , 2015, International journal of pharmaceutics.

[28]  R. Yumoto,et al.  Expression and function of PEPT2 during transdifferentiation of alveolar epithelial cells. , 2013, Life sciences.

[29]  L. Campbell,et al.  Constitutive Expression of P-Glycoprotein in Normal Lung Alveolar Epithelium and Functionality in Primary Alveolar Epithelial Cultures , 2003, Journal of Pharmacology and Experimental Therapeutics.

[30]  M. Tekin,et al.  A mutation in SLC22A4 encoding an organic cation transporter expressed in the cochlea strial endothelium causes human recessive non-syndromic hearing loss DFNB60 , 2016, Human Genetics.

[31]  M. Gumbleton,et al.  RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. , 2009, The Journal of pharmacy and pharmacology.

[32]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.

[33]  T. Terasaki,et al.  Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. , 2011, Journal of pharmaceutical sciences.

[34]  P. Högger,et al.  Methacholine delays pulmonary absorption of inhaled β(2)-agonists due to competition for organic cation/carnitine transporters. , 2012, Pulmonary pharmacology & therapeutics.

[35]  S. Rafii,et al.  Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacity , 2013, Respiratory Research.

[36]  C. Luscombe,et al.  Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model , 2016, Pharmaceutical Research.

[37]  Simon J. F. Macdonald,et al.  Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet? , 2009, J. Chem. Inf. Model..

[38]  Nilesh Patel,et al.  Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  K. Bleasby,et al.  The organic cation transporter OCT2 mediates the uptake of β‐adrenoceptor antagonists across the apical membrane of renal LLC‐PK1 cell monolayers , 2000, British journal of pharmacology.

[40]  D. Pritchard,et al.  Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Praveen M. Bahadduri,et al.  Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. , 2008, American journal of respiratory cell and molecular biology.

[42]  C. Ehrhardt,et al.  Salbutamol is actively absorbed across human bronchial epithelial cell layers. , 2005, Pulmonary pharmacology & therapeutics.

[43]  T. Tsuruo,et al.  Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue , 1990 .

[44]  Nicolas Grégoire,et al.  Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam , 2016, Antimicrobial Agents and Chemotherapy.

[45]  C. Ehrhardt,et al.  Functional expression of nicotine influx transporter in A549 human alveolar epithelial cells. , 2016, Drug metabolism and pharmacokinetics.

[46]  S. Halldorsson,et al.  Drug Delivery Characteristics of the Progenitor Bronchial Epithelial Cell Line VA10 , 2012, Pharmaceutical Research.

[47]  Ben Forbes,et al.  The Isolated Perfused Lung for Drug Absorption Studies , 2008 .

[48]  B. Forbes,et al.  In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  J. Castle,et al.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[50]  B. Forbes,et al.  A Comparison of Drug Transport in Pulmonary Absorption Models: Isolated Perfused rat Lungs, Respiratory Epithelial Cell Lines and Primary Cell Culture , 2017, Pharmaceutical Research.

[51]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.

[52]  M. Welsh,et al.  Development of cystic fibrosis and noncystic fibrosis airway cell lines. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[53]  Ben Forbes,et al.  Human respiratory epithelial cell culture for drug delivery applications. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[54]  T. Nakanishi,et al.  Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis , 2015, PloS one.

[55]  Michael Levin Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[56]  T. Terasaki,et al.  Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism Correlation of Organic Cation/Carnitine Transporter 1 and Multidrug Resistance-Associated Protein 1 Transport Activities With Protein Expression Levels in Primary Cultured Human Tracheal, Bronchial, and Alveolar Epithelial Cells , 2016 .

[57]  T. Terasaki,et al.  Drug Transporter Protein Quantification of Immortalized Human Lung Cell Lines Derived from Tracheobronchial Epithelial Cells (Calu-3 and BEAS2-B), Bronchiolar-Alveolar Cells (NCI-H292 and NCI-H441), and Alveolar Type II-like Cells (A549) by Liquid Chromatography-Tandem Mass Spectrometry. , 2015, Journal of pharmaceutical sciences.

[58]  W. Couet,et al.  P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model , 2009, Antimicrobial Agents and Chemotherapy.

[59]  U. Fischer,et al.  Human alveolar epithelial cells expressing tight junctions to model the air-blood barrier. , 2016, ALTEX.

[60]  Min-Ki Lee,et al.  Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. , 2007, Journal of pharmaceutical sciences.

[61]  Bill Newman,et al.  Functional variants of OCTN cation transporter genes are associated with Crohn disease , 2004, Nature Genetics.

[62]  C. Ehrhardt,et al.  In vitro cell culture models for the assessment of pulmonary drug disposition , 2008 .

[63]  M. Weiss,et al.  Pharmacokinetics of idarubicin in the isolated perfused rat lung: effect of cinchonine and rutin , 2003, Anti-cancer drugs.

[64]  S. Golz,et al.  Discovery of the ergothioneine transporter. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Margareta Hammarlund-Udenaes,et al.  Development of a Novel Lung Slice Methodology for Profiling of Inhaled Compounds. , 2016, Journal of pharmaceutical sciences.

[66]  D. Wall,et al.  Permeability Characteristics of Calu-3 Human Bronchial Epithelial Cells: In Vitro - In Vivo Correlation to Predict Lung Absorption in Rats , 2002, Journal of drug targeting.

[67]  Mark Gumbleton,et al.  Challenges in inhaled product development and opportunities for open innovation. , 2011, Advanced drug delivery reviews.

[68]  S J Enna,et al.  Absorption of saccharides and urea from the rat lung. , 1972, The American journal of physiology.

[69]  H. Daniel,et al.  The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology , 2004, Pflügers Archiv.

[70]  C. Vancheri,et al.  The lung as a privileged site for the beneficial actions of PGE2. , 2004, Trends in immunology.

[71]  K. Delank,et al.  Association of rheumatoid arthritis with ergothioneine levels in red blood cells: a case control study. , 2006, The Journal of rheumatology.

[72]  T. Nakanishi,et al.  Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. , 2010, Molecular pharmaceutics.

[73]  R. Yumoto,et al.  Comparison of Albumin Uptake in Rat Alveolar Type II and Type I-like Epithelial Cells in Primary Culture , 2008, Pharmaceutical Research.

[74]  T. Tsuruo,et al.  Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  T. Terasaki,et al.  Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: Involvement of a pyrilamine-sensitive organic cation transport process , 2013, Neurochemistry International.

[76]  Yoshinobu Nakamura,et al.  OATP2A1/SLCO2A1-mediated prostaglandin E2 loading into intracellular acidic compartments of macrophages contributes to exocytotic secretion. , 2015, Biochemical pharmacology.

[77]  Steven K. Huang,et al.  Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. , 2008, American journal of respiratory cell and molecular biology.

[78]  C. Ehrhardt,et al.  In vitro cell culture models for the assessment of pulmonary drug disposition. , 2008, Expert opinion on drug metabolism & toxicology.

[79]  D. Aronoff,et al.  Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[80]  M. Tomita,et al.  Gene Knockout and Metabolome Analysis of Carnitine/Organic Cation Transporter OCTN1 , 2010, Pharmaceutical Research.

[81]  J. Duarte,et al.  Paraquat Poisonings: Mechanisms of Lung Toxicity, Clinical Features, and Treatment , 2008, Critical reviews in toxicology.

[82]  J. Locker,et al.  Failure of Postnatal Ductus Arteriosus Closure in Prostaglandin Transporter–Deficient Mice , 2010, Circulation.

[83]  H. Koepsell The SLC22 family with transporters of organic cations, anions and zwitterions. , 2013, Molecular aspects of medicine.

[84]  T. Nakanishi,et al.  A role of prostaglandin transporter in regulating PGE₂ release from human bronchial epithelial BEAS-2B cells in response to LPS. , 2013, The Journal of endocrinology.

[85]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[86]  Nicolas Grégoire,et al.  Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 1. Ciprofloxacin, Moxifloxacin, and Grepafloxacin , 2014, Antimicrobial Agents and Chemotherapy.

[87]  Ken Grime,et al.  Optimisation of DMPK by the inhaled route: challenges and approaches. , 2012, Current drug metabolism.

[88]  C. Ehrhardt,et al.  Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. , 2012, Therapeutic delivery.

[89]  T. Terasaki,et al.  Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine. , 2016, Molecular pharmaceutics.

[90]  Tetsuya Terasaki,et al.  Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. , 2013, Journal of pharmaceutical sciences.

[91]  T. Terasaki,et al.  Pharmacoproteomics-Based Reconstruction of In Vivo P-Glycoprotein Function at Blood-Brain Barrier and Brain Distribution of Substrate Verapamil in Pentylenetetrazole-Kindled Epilepsy, Spontaneous Epilepsy, and Phenytoin Treatment Models , 2014, Drug Metabolism and Disposition.

[92]  Carsten Kneuer,et al.  Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o–: implications for the use of this cell line as an in vitro model for bronchial drug absorption studies , 2002, Cell and Tissue Research.

[93]  D. Horn,et al.  Mutations in the prostaglandin transporter encoding gene SLCO2A1 Cause primary hypertrophic osteoarthropathy and isolated digital clubbing , 2012, Human mutation.

[94]  M. Gumbleton,et al.  Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. , 2011, Advanced drug delivery reviews.

[95]  Hong Wang,et al.  Association of single nucleotide polymorphism rs3792876 in SLC22A4 gene with autoimmune thyroid disease in a Chinese Han population , 2015, BMC Medical Genetics.

[96]  S. Randell,et al.  Novel human bronchial epithelial cell lines for cystic fibrosis research. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[97]  T. Nakanishi,et al.  In vivo evidence of organic cation transporter-mediated tracheal accumulation of the anticholinergic agent ipratropium in mice. , 2013, Journal of pharmaceutical sciences.

[98]  Claus-Michael Lehr,et al.  Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD , 2016 .

[99]  Yusuke Nakamura,et al.  An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis , 2003, Nature Genetics.

[100]  V. Schuster,et al.  Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). , 1996, The Journal of clinical investigation.

[101]  L. Gustavsson,et al.  Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. , 2013, Journal of medicinal chemistry.

[102]  A. Rubbert,et al.  Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn’s disease , 2005, Gut.

[103]  A. Lundqvist,et al.  Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs , 2016, CPT: pharmacometrics & systems pharmacology.

[104]  M. Gumbleton,et al.  P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers , 2007, Cell and Tissue Research.

[105]  C. Ehrhardt Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines , 2017, Pharmaceutical Research.

[106]  M. Gumbleton,et al.  Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[107]  Ben Forbes,et al.  In‐vitro respiratory drug absorption models possess nominal functional P‐glycoprotein activity , 2009, The Journal of pharmacy and pharmacology.

[108]  Hans Lennernäs,et al.  Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. , 2003, Journal of pharmaceutical sciences.

[109]  R. Yumoto,et al.  Functional Expression of PEPT2 in the Human Distal Lung Epithelial Cell Line NCl-H441 , 2015, Pharmaceutical Research.

[110]  T. Matsui,et al.  A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter , 2015, PLoS genetics.

[111]  C. Ehrhardt,et al.  Transport of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) in human respiratory epithelial cells. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[112]  Sandra A G Visser,et al.  Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions. , 2016, Journal of aerosol medicine and pulmonary drug delivery.